Guselkumab (TREMFYA) injection

Weight: ____________ kg  Height: ____________ cm

Allergies: __________________________________________

Diagnosis Code: ___________________________________

Treatment Start Date: ____________  Patient to follow up with provider on date: ____________

**This plan will expire after 365 days at which time a new order will need to be placed**

GUIDELINES FOR ORDERING

1. Send FACE SHEET and H&P or most recent chart note.
2. Tuberculosis screening (Tuberculin skin test or QuantiFERON Gold blood test) must result negative within the past year. Do not administer to patients with an active TB infection. Monitor closely for signs/symptoms of active TB during and after guselkumab treatment.
3. Guselkumab may increase the risk of infections, particularly upper respiratory tract infections, gastroenteritis, tinea infections, and herpes simplex infections. Consider the risks versus benefits prior to treatment initiation in patients with a history of chronic or recurrent infection. Treatment must not be initiated in patients with clinically important active infections until it is resolved or treated. Monitor for signs and symptoms of infection.
4. Patients must be brought up to date with all immunizations before initiating therapy. Live vaccines must not be given concurrently.

PRE-SCREENING: (Results must be available prior to initiation of therapy):

☐ QuantiFERON Gold test results included with orders
☐ Tuberculin skin test results included with orders

MEDICATIONS:

- guselkumab (TREMFYA) injection 100 mg, subcutaneous, ONCE

  Interval: (must check at least one)
  ☐ Initiation: week 0 ____________  and week 4 ____________
  ☐ Maintenance: every 8 weeks thereafter

NURSING ORDERS:

1. Prior to guselkumab administration, remove prefilled syringe from the refrigerator and allow to warm at room temperature for 30 minutes in original carton. Do not warm in any other way
2. Administer subcutaneously into front of thighs, lower abdomen (except for 2 inches around navel) or back of upper arms. Do not inject into areas where the skin is tender, bruised, red, hard, thick, scaly, or affected by psoriasis.
4. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes.
By signing below, I represent the following:
I am responsible for the care of the patient (who is identified at the top of this form);
I hold an active, unrestricted license to practice medicine in: □ Oregon □ ________________ (check box that corresponds with state where you provide care to patient and where you are currently licensed. Specify state if not Oregon);

My physician license Number is # ________________ (MUST BE COMPLETED TO BE A VALID PRESCRIPTION); and I am acting within my scope of practice and authorized by law to order Infusion of the medication described above for the patient identified on this form.

Provider signature: ____________________________  Date/Time: ____________________________
Printed Name: ____________________________  Phone: ____________  Fax: ____________

OLC Central Intake Nurse:
Phone: 971-262-9645 (providers only) Fax: 503-346-8058

Please check the appropriate box for the patient’s preferred clinic location:

☐ Beaverton
OHSU Knight Cancer Institute
15700 SW Greystone Court
Beaverton, OR 97006
Phone number: 971-262-9000
Fax number: 503-346-8058

☐ NW Portland
Legacy Good Samaritan campus
Medical Office Building 3, Suite 150
1130 NW 22nd Ave.
Portland, OR 97210
Phone number: 971-262-9600
Fax number: 503-346-8058

☐ Gresham
Legacy Mount Hood campus
Medical Office Building 3, Suite 140
24988 SE Stark
Gresham, OR 97030
Phone number: 971-262-9500
Fax number: 503-346-8058

☐ Tualatin
Legacy Meridian Park campus
Medical Office Building 2, Suite 140
19260 SW 65th Ave.
Tualatin, OR 97062
Phone number: 971-262-9700
Fax number: 503-346-8058

Infusion orders located at: www.ohsuknight.com/infusionorders